Sectors:
Locations:
Min Investment:
Max Investment:
Target Investment:
Master of Business Administration - MBA
Strategy, Executive Education
Finance & Risk Management, Executive Education
Innovation, Executive Education
Diploma, Digital Marketing
2019
2019
Golden Seeds: 180+ million AUM angel network with current investments in 82 early-stage, women-led companies. Identify, mentor, and evaluate life science companies affiliated with Columbia and Johns Hopkins Technology Ventures, NYU Biolabs, JLABS (Johnson & Johnson), and other sources of investment opportunities. Advise portfolio company boards, founders, and executives. • Led 6 deals (due diligence, deal memos, presentations, advisory) in over-the-counter (OTC) medicines, medical devices, CBD therapeutics, women’s health, and marketing technology. • Advised medical device portfolio company through IPO that delivered 4.4X, 28-month return to Golden Seeds investors. • Built New York Metro Area life science ecosystem, including extensive network of investors and multi-disciplinary start-up experts.
2018
Inspired Solutions: Strategy consultancy focused on go-to-market and geographic expansion for health & wellness clients ranging from start-ups to global enterprises. Work closely with client company executive teams and boards to develop and execute capital formation, plus revenue & EBITDA growth strategies. Representative engagements include: • Launched French wellness brand in the US. Included creating and executing go-to-market plan and establishing operations. Successful geographic expansion provided further product proof-of-concept and revenue growth, which enabled $2.7 million Series A round. • Collaborated with socio-economic trend & innovation agency to turn around EU personal care brand with 9 quarters of declining sales. Conducted qualitative & quantitative research that drove rebranding and new product development. Restored growth; beat client goals. • Developed German go-to-market strategy and roadmap for UK dietary supplement manufacturer. Identified and analyzed competitors, omni-channel distribution opportunities, marketing strategies, and costs. Delivered plan that met client’s EBITDA growth goals. • Worked with several early-stage US clients on comprehensive and specific strategies for market identification, capital formation, product/market fit, IP protection, and scalability.
2013 - 2018
2013 - 2018
WBA: $139 billion, US-headquartered retail pharmacy and health, wellness & beauty company with 12,500 locations across the US, Europe, and Latin America (NSDQ: WBA). Owned $3.1 billion P&L for wholesale distribution channel/brand that served 6,800 independent retail pharmacies in 9 European countries (US General Manager equivalent). Managed 2 direct reports and 9-person Country Lead matrix organization. Presented to Board of Directors. Reported to Managing Director, International Wholesale Pharmacy Division. • Delivered 4%, 4-year compound annual revenue growth rate in mature channel. Met/beat annual financial and member quality goals. • Managed 2015 integration of 1,100-pharmacy German marketing cooperative; beat retention targets; grew to 1,750 German members in 3 years. • Developed and executed ancillary product & services-based strategy and offered new tools (category management, promotions, organization development) that enabled member pharmacies to grow earnings because of membership in the Alphega Pharmacy Group. • Created data-driven Close to You brand advertising campaign and consumer closeness training program. Negotiated high-6-figure sponsorship with global FMCG company in exchange for new distribution agreement with Alphega and member pharmacies. • Worked closely with country organizations, including pharmacist boards, WBA sales teams, and other WBA entities.
2006 - 2013
2006 - 2013
Merck: €22 billion, global healthcare, life science, and electronics company (FWB: MRK). CMO of new, high-9-figure division. Built 22-person, 14-nationality, global team. Worked closely with C-level colleagues. Executive Board member. Reported to Division President. • Played critical role in delivering 5%, 6-year compound annual revenue growth rate across operations in 60 countries. Met financial targets each year. • Created and executed growth strategy focused on highest-potential brands. Relaunched brands. Developed new products (OTC meds, dietary supplements); produced 30%+ of revenue from 2009 forward. Entered China and India. • Recruited and developed high-performing team. Provided talent bench for other divisions.
1994 - 2006
1994 - 2006
BHI: OTC medicines division of £5 billion Boots Group, a UK-headquartered health & beauty retailer and pharmacy chain (now Walgreens Boots Alliance). Acquired by Reckitt Benckiser in Q4/05.
1988 - 1994
1988 - 1994
Unilever: €60 billion, global consumer packaged goods company (LSE: ULVR).